Article

Circulating 25-Hydroxyvitamin D Levels and Frailty Status in Older Women

Center for Chronic Disease Outcomes Research, VA Medical Center, and Department of Medicine, University of Minnesota, M.P.H., One Veterans Drive (111-0), Minneapolis, Minnesota 55417, USA.
The Journal of Clinical Endocrinology and Metabolism (Impact Factor: 6.31). 12/2010; 95(12):5266-73. DOI: 10.1210/jc.2010-2317
Source: PubMed

ABSTRACT Vitamin D deficiency and frailty are common with aging, but the association between these conditions is uncertain.
To determine the association between 25-hydroxyvitamin D (25(OH)D) levels and prevalent and incident frailty status among older women.
Cross-sectional and longitudinal analyses of a prospective cohort study.
Four U.S. centers.
6307 women aged≥69 years.
Frailty status classified as robust, intermediate stage, or frail at baseline; and robust, intermediate stage, frail, or dead (all-cause mortality) at follow-up an average of 4.5 years later.
At baseline, there was a U-shaped association between 25(OH)D level and odds of frailty with the lowest risk among women with levels 20.0-29.9 ng/ml (referent group). Compared with this group, the odds of frailty were higher among those with levels<15.0 ng/ml [multivariable odds ratio (MOR) 1.47, 95% confidence interval (CI), 1.19-1.82], those with levels 15.0-19.9 ng/ml (MOR 1.24, 95% CI 0.99-1.54), and those with levels≥30 ng/ml (MOR 1.32, 95% CI 1.06-1.63). Among 4551 nonfrail women at baseline, the odds of frailty/death (vs. robust/intermediate) at follow-up appeared higher among those with levels 15.0-19.9 ng/ml (MOR 1.21, 95% CI 0.99-1.49), but the CI overlapped 1.0. The odds of death (vs. robust/intermediate/frail at follow-up) was higher among those with levels<15.0 ng/ml (MOR 1.40, 95% CI 1.04-1.88) and those with levels 15.0-19.9 ng/ml (MOR 1.30, 95% CI 0.97-1.75), although the latter association did not quite reach significance.
Lower (<20 ng/ml) and higher (≥30 ng/ml) levels of 25(OH)D among older women were moderately associated with a higher odds of frailty at baseline. Among nonfrail women at baseline, lower levels (<20 ng/ml) were modestly associated with an increased risk of incident frailty or death at follow-up.

0 Followers
 · 
96 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Many of the symptoms, consequences, and risk factors for frailty are shared with late-life depression. However, thus far, few studies have addressed the conceptual and empirical interrelationships between these conditions. This review synthesizes existing studies that examined depression and frailty among older adults and provides suggestions for future research.MethodsA search was conducted using PubMed for publications through 2010. Reviewers assessed the eligibility of each report and abstracted information on study design, sample characteristics, and key findings, including how depression and frailty were conceptualized and treated in the analysis.ResultsOf 133 abstracted articles, 39 full-text publications met inclusion criteria. Overall, both cross-sectional (n = 16) and cohort studies (n = 23) indicate that frailty, its components, and functional impairment are risk factors for depression. Although cross-sectional studies indicate a positive association between depression and frailty, findings from cohort studies are less consistent. The majority of studies included only women and non-Hispanic Whites. None used diagnostic measures of depression or considered antidepressant use in the design or analysis of the studies.ConclusionsA number of empirical studies support for a bidirectional association between depression and frailty in later life. Extant studies have not adequately examined this relationship among men or racial/ethnic minorities, nor has the potential role of antidepressant medications been explored. An interdisciplinary approach to the study of geriatric syndromes such as late-life depression and frailty may promote cross-fertilization of ideas leading to novel conceptualization of intervention strategies to promote health and functioning in later life. Copyright © 2011 John Wiley & Sons, Ltd.
    International Journal of Geriatric Psychiatry 09/2012; 27(9). DOI:10.1002/gps.2807 · 3.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: De par ses conséquences et sa prévalence élevée, la fragilité peut être considérée comme un problème majeur chez le sujet âgé. Son origine est multifactorielle, compte tenu de la fréquence des déficits nutritionnels, leurs rôles quant à la survenue de la fragilité doivent être connus. Il est désormais bien établi que des apports protéiques et énergétiques insuffisants sont directement reliés à la fragilité par l’intermédiaire de plusieurs de ses composantes. Les données récentes soulignent aussi toute l’importance des micronutriments dont le déficit conduit à une fragilité indépendamment du rôle des macronutriments. Les données disponibles indiquent que les aspects qualitatifs doivent aussi être pris en compte dans l’alimentation des personnes âgées. Un suivi tenant compte de ces différents aspects apparaît un élément majeur dans la stratégie de prévention et de prise en charge de la fragilité.
    Les cahiers de l année gérontologique 04/2012; 4(1). DOI:10.1007/s12612-012-0256-z
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: People with neurodevelopmental disorders and intellectual disabilities have much greater health care needs. Mainly staying indoors, such people generally have low 25-hydroxyvitamin D (25(OH)D) concentrations. The Vitamin D Task Force of the American Academy of Developmental Medicine and Dentistry (AADMD) reviewed the evidence of 25(OH)D concentrations that benefit the health of persons with developmental disabilities. Maintaining recommended optimal serum 25(OH)D concentrations year long will benefit skeletal development in infants, children, and adolescents, and benefit musculoskeletal health and neuromuscular coordination in adult patients, and decrease risk of falls. Maintaining optimal concentrations decreases risks and severities of autoimmune diseases, cardiovascular disease, many types of cancer, dementia, types 1 and 2 diabetes mellitus, and respiratory tract infections. Other benefits include improved dental and oral health and improved physical performance. The Task Force recommends that 25(OH)D concentrations for optimal health to be in the range of 75 to 125 nmol/L, which can be achieved using between 800 and 4000 IU/day vitamin D3 and sensible exposure to solar UVB radiation. The paper also discusses the potential risks of higher 25(OH)D concentrations, the evidence from and limitations of randomized controlled trials, and the recommendations by various groups and agencies.
    Nutrients 03/2015; 7(3):1538-1564. DOI:10.3390/nu7031538 · 3.15 Impact Factor